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86 The Journal of Thoracic and Cardiobjectives: We have developed a stentless pericardial mitral valve prosthesis in 2
onfigurations; the purposes of this acute study in sheep were to assess (1) valve
esign and implant technique; (2) valve performance; and (3) acute effects on
ostimplant left ventricular function.
ethods: A stentless bovine pericardial bileaflet valve was developed with the
ntent to preserve annular–papillary muscle continuity. This valve, in 2 configura-
ions—with (n  5) and without (n  5) flap chordae—was implanted in 10 sheep
mean weight 73  9 kg). Epicardial echocardiography was performed to assess
alve performance. Load-independent left ventricular function was also estimated
efore implantation (baseline), 1 hour after discontinuing cardiopulmonary bypass
rest), and during dobutamine stimulation using conductance technology.
esults: Implantation was easily accomplished for both configurations. Both con-
gurations had low transvalvular pressure (mean 2.1 1.2 mm Hg at rest; 2.2 1.0
m Hg with dobutamine stimulation with flap chordae; 1.7  0.5 mm Hg and 1.6
0.3 mm Hg without flap chordae). No mitral regurgitation was observed in 8
heep, and mild regurgitation was seen in 2 sheep. Compared with baseline, slope
f maximum rate of change of left ventricular pressure–end-diastolic volume
elation increased with stimulation both with flap chordae (52 41 mm Hg · s1
· mL1, P  .0005) and without (20  12 mm Hg · s1 · mL1, P  .003).
onclusions: Both configurations of this newly designed stentless mitral biopros-
hesis, which preserves annular–papillary muscle continuity using different novel
urgical implantation techniques, demonstrated reliable valve performance, with
ow transvalvular pressure gradients, minimal regurgitation, and acutely preserved
ostimplant left ventricular function. Further chronic study is needed to verify these
esults and evaluate reliability of implantation procedures, biocompatibility, and
urability.
reservation of mitral annulus–papillary muscle continuity during mitral valve
surgery is crucial to preserving postoperative left ventricular (LV) function
and geometry.1,2 This concept has been applied to valve repair procedure3-5
nd technical modifications to preserve this continuity6-8 have been added to val
eplacement to improve survival.7-10
In the aortic position, stentless bioprostheses are claimed to have lower trans-
alvular gradients, better hemodynamic performance, and enhanced durability com-
ared with stented bioprostheses.11 Development of mitral stentless bioprosthes
as stimulated by the same promise. Several investigators have reported experi-
ental and clinical results of stentless bioprostheses,12-16 but these valves hav
arely been implanted because of difficult design constraints imposed by anatomic
nd functional complexity of the native mitral valve and its subvalvular apparatus.
he technical challenge of implanting mitral allografts and poor midterm clinicalesults due to graft failure and failure to remain competent over time have resulted
vascular Surgery ● April 2007
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ETn a high incidence of explantation.17,18 Thus, they have no
ecome a useful alternative to stented mitral prostheses.
Because of these shortcomings and greater understand-
ng of the anatomy and physiologic mechanisms of the mitral
alve–LV complex, a stentless mitral bioprosthesis19-22 that
an be implanted with relative ease, exhibits physiologic valve
erformance, and preserves annular–papillary muscle continu-
ty might be a competitive option for treating unrepairable
itral valve disease. We have developed a stentless pericar-
ial mitral valve prosthesis in 2 configurations based on the
rinciples of ease of implantation and preservation of mitral
nnulus–papillary muscle continuity. The purposes of this
cute study in sheep were to assess (1) valve design and
mplantation technique, (2) valve performance, and (3)
cute effects on postimplantation LV function.
aterials and Methods
tentless Mitral Valve Design and Implantation
echniques
he new valve design is based on the human mitral valve 3-D
onfiguration. In human anatomy, the aortic and mitral valves
ccupy the same opening in the in the base of the left ventricle, but
hey lie at an angle of 40° to one another. Thus, the anterior mitral
eaflet forms the watershed between inflow and outflow streams of
he left ventricle. Mitral leaflets form a continuous veil, attached as
muff to the circumference of the mitral annulus. The free edge of
his veil hangs into the left ventricle and is split by indentations,
one of which reach the annulus.
The length of annular attachment of the anterior leaflet is half
hat of the posterior leaflet. The maximum depth of the anterior
eaflet, measured from its annular attachment to apex, is approxi-
ately twice that of the posterior leaflet. Thus, the mitral valve is
onical in shape, with the inlet larger than the outlet. Because the
nterior and posterior leaflets are not of equal height, the plane of
he outlet orifice does not correspond with that of the annulus but
s oblique, sitting in the plane of the outlet orifice to some extent,
hich compensates for the size discrepancy. Although the anterior
nd posterior leaflets differ in shape, annular attachment, and
eight, their surface areas are approximately equal. So, we de-
igned and fabricated a new bileaflet stentless valve from 1 piece
f 0.65% glutaraldehyde-treated bovine pericardium that mimics
he human mitral valve, preserving all these anatomic features in
imension and shape.
Two configurations were developed to cope with different
itral valve pathologies. Both were designed with the implantation
riteria of preserving annulus–papillary muscle continuity, main-
Abbreviations and Acronyms
CPB  cardiopulmonary bypass
F-SMV stentless mitral valve with flap chordae
LV  left ventricular
SMV  stentless mitral valveaining the flexible physiologic contraction of the mitral annulus, c
The Journal of Thoracicemoving diseased valve tissue, and replacing the valve with
orrect orientation and appropriate size. One configuration, the
MV (Figure 1), replaced the native mitral valve leaflets bu
he native subvalvular apparatus intact. The other, F-SMV (Fi
), replaced both leaflets and chordae; it has 2 flap ch
tructures extending from each leaflet that are attached to the head
f the native papillary muscles.
cute Animal Study
his stentless bioprosthesis was implanted in 10 healthy Dorsett
heep (mean weight 73  9 kg), 5 in each configuration. Success
f implantation technique and valve performance were evaluated
ith epicardial echocardiography. Acute hemodynamic indices
nd volumetric data were also recorded before implantation (base-
ine), 1 hour after discontinuing cardiopulmonary bypass (CPB;
est period), and during dobutamine stimulation. The study was
pproved by Cleveland Clinic’s Institutional Animal Care and Use
ommittee. All animals received humane care in compliance with
he “Guide for the Care and Use of Laboratory Animals.”23
alve Implantation
heep were anesthetized with inhalational isoflurane and venti-
ated through an endotracheal tube; anesthesia was maintained
ith isoflurane (0.5%–2.5%). Animals were placed in the right
ateral position, and electrocardiography leads were attached to
heir extremities. After instrumentation and baseline hemodynamic
easurements were obtained as detailed in Appendix E1, left
horacotomy was performed and the pericardium opened longitu-
inally. CPB was established with left carotid artery and pulmo-
ary trunk–right atrium cannulation after systemic heparinization
3 mg · kg1). After the ascending aorta was clamped, the heart
as arrested with antegrade cold blood cardioplegic solution. The
eft atrial free wall was then opened and mitral valve components
valuated and measured directly.
For SMV implantation, its anterior and posterior leaflets were
ailored by trimming the free edges to match direct measurements
f native anterior and posterior leaflet heights. SMV annulus size
as chosen to match that of the native annulus. After the SMV was
repared, the native anterior leaflet was dissected from the mitral
nnulus and the clear zone resected, but the leaflet’s rough zone
nd corresponding primary and secondary chordae were preserved
Figure 3, A and B). The free edge of the anterior SMV leaflet
hen sutured to the preserved part of the native anterior leaflet with
-0 Ethibond (polyester; Ethicon, Inc, Somerville, NJ) continuous
uture. The same procedures were repeated for the posterior leaflet,
reserving native primary and secondary chordae. The inflow
ewing margin was then sutured to the native mitral annulus using
4–0 polypropylene continuous suture.
For F-SMV implantation, length between the commissural portion
f the F-SMV inflow and tip of the flap chordae (F-SMV height) was
etermined by measuring directly the distance between the papillary
uscle head and commissural portion of the native annulus on each
ommissural side; tips of the flap chordae were trimmed to match.
-SMV annular size was determined as for SMV. Native mitral
eaflets and chordae were then totally excised, and tips of the flap
hordae of the anterolateral commissural side were sutured to the
and Cardiovascular Surgery ● Volume 133, Number 4 987
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ETnterolateral papillary muscle head with 4-0 Ethibond mattress suture
ith a pledget (Figure 3, C and D). Tips of the flap chordae of
ther commissural side were sutured to the posteromedial papillary
uscle head. The sewing margin on the F-SMV inflow was then
utured to the native annulus as for SMV.
valuating the Valve
fter implantation of each valve, leaflet coaptation, valve orien-
ation, and mitral regurgitation were evaluated by infusing saline
olution under pressure into the left ventricle. After closing the left
trium and unclamping the aorta, CPB was discontinued. To obtain
table hemodynamics in the post-CPB period, a low dose of
orepinephrine was used in 3 of 5 sheep in the SMV group (0.04
0.05 g · kg1 · min1) and 2 of 5 in the F-SMV group (0.05
0.07 g · kg1 · min1).
After decannulation, the hemodynamic instrumentations (con-
uctance catheter, flow probe, left atrial catheter) were replaced.
picardial 2-D and Doppler echocardiography were performed to
valuate leaflet motion, regurgitation, transvalvular mean pressure
radient, LV volumes, and valve performance. Hemodynamic
ndices and LV volume data were recorded at steady state and after
ransient inferior vena cava occlusion 1 hour after discontinuing
Figure 1. Stentless mitral valve. A, Inflow fronFigure 2. Stentless mitral valve with flap chordae. A, inflow
88 The Journal of Thoracic and Cardiovascular Surgery ● ApriPB (rest). The same observations were again recorded during
obutamine (0.5 to 1 g · kg1 · min1) stimulation.
When all procedures were finished, the animal was killed with
n overdose of intravenous pentobarbital (100 mg · kg1) and
otassium chloride (100 mEq). At necropsy, the implanted valve
as evaluated macroscopically.
ata Analysis
etails of extracting hemodynamic indices are given in Appendix E2.
All data are summarized as mean  SD. To account for lack of
ndependence from multiple measurements evaluated from the same
alves, longitudinal methods (SAS PROC MIXED; SAS Institute,
nc, Cary, NC) were used.24 The variables systemic vascular res-
ance (SVR) and slope of maximum rate of change of left ventricular
ressure–end-diastolic-volume relation were logarithmically trans-
ormed to meet the distributional assumption of normality before
nalysis. Univariable models were initially formed to test overall
hanges from baseline for each hemodynamic and cardiac function
easure. The F-SMV group variable was then added to assess group
ifferences. Planned contrasts were used to test within-group changes
rom baseline to rest, baseline to stimulation, and rest to stimulation.
tatistical analyses were performed using SAS version 8.2.
iew. B, Outflow frontal view. C, Lateral view.tal vfrontal view. B, Outflow frontal view. C, Lateral view.
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ETesults
mplantation Feasibility and Reproducibility
he stentless pericardial mitral valve prosthesis, in both
onfigurations, was easily and successfully implanted. By
chocardiography, both SMV and F-SMV demonstrated
ide physiologic leaflet opening and secure closing withoutThe Journal of Thoraciceaflet restriction, mitral stenosis, systolic anterior motion,
rolapse, or tethering (Figures 4 – 6). In 1 of 5 SMV
rade 1 (mild) mitral regurgitation was detected at rest and
ith dobutamine stimulation; at necropsy, a fold was noted
n the SMV’s posterior leaflet, resulting in a segmental gap
f leaflet coaptation. This fold was formed by suturing the
Figure 3. Schematic images of stent-
less valve implantation. A and B, Out-
flow of SMV was sutured to free edges
of native leaflets, and inflow was to
native mitral annulus. C and D, Flap
chordae of F-SMV were sutured to
papillary muscle heads, and inflow
was to native mitral annulus. SMV,
stentless mitral valve.
Figure 4. Stentless mitral valve (SMV): postim-
plant epicardial 2-D echocardiography during di-
astolic and systolic phases. Note wide open
valve area and normal level of leaflet coaptation
of the new prosthesis. A and B, 4-chamber view.
C and D, Short-axis view.and Cardiovascular Surgery ● Volume 133, Number 4 989
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ETedundantly wider SMV leaflet to the native leaflet. No
egurgitation was found in the remaining 4 SMV cases at
est or with stimulation. Grade 1 mitral regurgitation was
etected at rest and with stimulation in 1 of 5 F-SMV cases.
egurgitation originated from the space between the flap
hordae that seemed to be formed by the difference in their
engths on the same commissural side. No regurgitation was
etected at rest or with stimulation in the remaining 4 of 5
-SMV cases.
cute Valve Performance
ean transvalvular pressure gradient was low (SMV: 1.7 
.5 mm Hg at rest, 1.6  0.3 mm Hg with stimulation;
-SMV: 2.1  1.2 mm Hg at rest, 2.2  1.0 mm Hg with
timulation). No statistically significant differences were
etected between rest and stimulation (SMV: P  .6; F-
MV: P  .8) or between SMV and F-SMV (P  .3).
Hemodynamics at baseline and acutely postimplant at
est and with dobutamine stimulation are summarized in
able 1. Heart rate increased with stimulation in 
roups. LV end-diastolic pressure remained at baseline
evel except for a decrease with stimulation in the SMV
roup. After valve implantation, cardiac output and stroke
olume were lower and pulmonary capillary wedge and left
trial pressures higher in both groups.
ostimplantation LV Function
V volumes were lower after valve replacement at both rest
nd exercise, as was LV stroke work (Table E1 and Figurq
90 The Journal of Thoracic and Cardiovascular Surgery ● Apri1). However, load-independent indices of contractil
ere preserved in both groups (Figures 7 and 8), as w
fficiency (Figure 8).
iscussion
easibility and Reproducibility
he 2 configurations of the novel stentless mitral valve
resented in this report were simply and physiologically
esigned to reproduce features of the native human mitral
alve. They employ anatomically and functionally ad-
anced concepts of preserving annulus–papillary muscle
ontinuity. Implantation techniques were relatively easy,
easible, and reproducible. We believe that ease of implan-
ation and good performance of the SMV stems from not
sing the papillary muscles as a supporting mechanism for
he prosthesis. For the F-SMV, ease and reproducibility of
he implant arise because there are only 2 flap chordae
xtensions, and these are sutured to the anterior side of each
apillary muscle head, a simple technique. Causes of mild
egurgitation were technical and can be eliminated by ac-
urate sizing of the prostheses and careful implantation.
pecifically, mild mitral regurgitation, observed in 1 animal
ith each valve configuration, demonstrates the importance
f avoiding leaflet redundancy, leading to folding on the one
and and (for F-SMV) disparity in flap chordae length on
he other.
Our valve differs in a number of ways from commer-
ially available stentless prostheses, such as the St Jude
edical Quattro (St Jude Medical, Inc, St Paul, Minn)
Figure 5. Stentless mitral valve with flap chor-
dae (F-SMV): postimplant epicardial 2-D echo-
cardiography during diastolic and systolic
phases shows a large valve orifice area, with
extent of opening and closing of the bioprosthe-
sis similar to that of the native mitral valve.
Anatomic mitral annular–papillary muscle integ-
rity is preserved. A and B, 4-chamber view. C and
D, Short-axis view.euadricusp mitral valve.16,25-27 The Quattro prosthesis has a
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ET-leaflet configuration, with a large pericardial tissue coap-
ation area that reduces risk of regurgitation. Each leaflet has
chordae-flap extension that occupies a large amount of LV
pace. We believe this quadricusp configuration leads to
onuniform opening and restricted transvalvular flow, as
ell as potential outflow obstruction in patients with a small
V cavity (such as occurs in mitral stenosis from rheumatic
alve disease). It is this very setting that is the primary
ndication for use of a prosthesis. Our design differs more
harply from the Medtronic stentless porcine xenograft pros-
hesis (Medtronic, Inc, Minneapolis, Minn),13 whose subval-
ular apparatus consists of a complex arrangement of chordae
ttached to 2 polyester tubes that are sutured to the tips of the
apillary muscles. Coaptation seems sensitive to accurate
ength of these papillary muscle tubes. Matching donor and
ost anatomy is a problem that makes the surgical procedure
echnically complex, just as it does for the Biocor porcine
tentless mitral valve28 (BioCor, Belohorizonte, Brazil). Ou
esign also differs from that of the stentless mitral pericardial
alve,29 which is fabricated on the operating room table w
quare or trapezoidal pieces of autologous or bovine pericar-
ium. The pericardial pieces are sutured together along their
ateral margins, creating a valvular body of a modified cylinder
r truncated cone. The lateral sutures are used as chordae to
ttach to the papillary muscles. This fabrication characteristic
ntroduces uncertainties and makes it difficult to achieve re-
roducible, reliable function. Further, durability is uncertain
ecause extensions of the lateral valve sutures are used to
ttach the chordae to the papillary muscle head. Our valve also
iffers from allograft mitral valves that suffer from complex
nd nonreproducible implantation techniques,30-32 particularly
ppropriate alignment of the subvalvular apparatus and secure
Figure 6. Postimplant epicardial color Doppler echoca
SMV, 4-chamber view; C, short-axis view. D and E, F-SM
show large valve orifice area with unrestricted centrand reliable papillary muscle anastomosis.33 t
The Journal of Thoraciccute Valve Performance
y echocardiography, both SMV and F-SMV demonstrated
ood physiologic valve performance without mitral stenosis
r LV outflow tract obstruction. Mean transvalvular pres-
ure gradient was lower than that of other prosthetic
alves.20-22,34 The increment in gradient with dobutami
timulation was within the expected physiologic range.
ostimplantation LV Function
n acute animal models, interrupting annulus-papillary conti-
uity impairs indices of LV contractile function, such as load-
ndependent slope of end-systolic pressure–volume loop and
aximum rate of change of left ventricular pressure,1,2 and
hese recover to baseline when annulus–papillary continuity is
eestablished.1 We did not observe a decrease in these -
es acutely after insertion of either SMV or F-SMV. With
timulation, some indices increased significantly, although
ot as much as might be anticipated. However, the dobut-
mine dose was low (0.5 or 1.0 g · kg1 · min1)
ecause sheep hearts are sensitive to it; higher doses easily
ause tachycardia, ventricular tachycardia, or ventricular
brillation. Also, a low dose of norepinephrine was used in
alf the sheep at both rest and stimulation. Need for inotro-
ic support following CPB may be linked to a depressed
yocardial state leading to the lower-than-expected in-
rease in contractility and cardiac output in response to
timulation.
imitations
his is a report of an acute assessment of the design,
evelopment, and implantation of a new stentless valve
rosthesis for the mitral position. It is only the first step in
raphy during diastolic and systolic phases. A and B,
-chamber view; F, short-axis view. Both bioprostheses
inar flow and competent valve closure.rdiog
V, 4
l lamhe ongoing process of testing the developmental concept of
and Cardiovascular Surgery ● Volume 133, Number 4 991
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9
EThe 2-valve configurations, the implantation techniques,
alve performance, and hemodynamic response.
We recognize the inherent limitations of acute hemody-
amic results. It is difficult to isolate the hemodynamic
ffects of the valve from hemodynamic impairment associ-
ted with CPB and transient cardiac ischemia.
onclusions
e have developed a novel stentless bileaflet mitral valve in
configurations, each preserving annular–papillary muscle
ontinuity by novel implantation techniques. Their config-
ration makes insertion easy and reproducible, although
ild mitral regurgitation observed with 1 implantation with
ach configuration emphasizes the challenge of accurate
easurements required for perfect valve function. Both
emonstrate low transvalvular pressure gradients in acute
nimal studies. Further chronic study is needed to verify
hese results and evaluate the reliability of implantation
rocedures and the biocompatibility and durability of the
alves.
Looking ahead, patients who are unsuitable for mitral
alve repair are candidates for these valves. Choice of
MV or F-SMV would depend on extent of disease. SMV
ould be used for localized leaflet lesions, such as thick-
ned leaflets causing mitral stenosis, enlarged or redun-
ant regurgitant myxomatous leaflets, or localized vege-
ations, in which the subvalvular apparatus is not
nvolved in the disease process and artificial chordae are
ot used.5 The F-SMV would be suitable for dise
nvolving both the leaflets and subvalvular apparatus.
ther applications include mitral leaflet extension or
artial mitral valve replacement as “a part of the wide
ange of techniques of mitral valve repair” for which
able 1. Hemodynamic data at baseline and acutely posti
SMV
Baseline Rest
R (beats/min) 96 9 104 18
O (L/min) 4.7 1.1 3.2 0.9*
V (mL) 50 14 31 10*
VEDP (mm Hg) 8 2 8  2
VR (dynes · s · m5) 1500 460 1970 840
VR (dynes · s · m5) 220 63 240 131
ean AoP (mm Hg) 87 13 79 11
ean CVP (mm Hg) 3 4 8  4*
ean PAP (mm Hg) 18 6 22  3†
ean PCWP (mm Hg) 10 5 15  4*
ean LAP (mm Hg) 5 4 13  3*
alues are expressed as mean  SD.
R, Heart rate; CO, cardiac output; SV, stroke volume; LVEDP, left ventricu
ascular resistance; AoP, arterial pressure; CVP, central venous pressure;
AP, left atrial pressure. *P  .001 versus baseline. †P  .05 versus basllografts have been proposed.20 S
92 The Journal of Thoracic and Cardiovascular Surgery ● Apriigure 7. Changes in load-independent slope of end-systolic
ressure–volume loop (Emax) and preload recruitable stroke work
PRSW). Emax (top) increased significantly with dobutamine stim-
lation in F-SMV group. Statistically significant changes in PRSW
ere not found at rest or with stimulation in either group. Bars
epresent 1 standard deviation. SMV, Stentless mitral valve; F-mplant at rest and with dobutamine stimulation
F-SMV
Stimulation Baseline Rest Stimulation
145 10*,‡ 111  11 116 16 128 22*
3.0 0.9* 5.4  0.5 3.0 0.8* 3.2 0.7*
21 6*,‡ 49  8 27  8* 25 6*
6 2†,‡ 6  2 5  1§ 7 4
2700 1860† 1290 220 1870 580 1890 430†
380 271 128  118 300 199 290 164
80 14 92  10 77 9† 91 12‡
6 4† 6  4 10  3* 9  4†
22 3† 19  6 29  8* 28 8*
13 5† 11  4 20  4* 17 4*
12 5* 11  4 18  5* 17 5†
lar end-diastolic pressure; SVR, systemic vascular resistance; PVR, pulmonary
PAP, pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure;MV, stentless mitral valve with flap chordae; DOB, dobutamine.
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Navia et al Evolving Technologyppendix E1: Surgical Procedures and Baseline
easurements
he left carotid artery and external jugular vein were isolated
hrough a lateral vertical neck incision. The artery was cannulated
ith an 8F sheath. A conductance catheter (SPC-562, Millar
nstruments, Inc, Houston, Tex) with 2 Millar pressure sensors was
nserted into the left ventricle and aortic root to record LV volume
nd pressure and aortic pressure; the catheter was positioned so
hat all 5 segments yielded good conductance signals. Blood con-
uctivity was calibrated in the Leycom sigma-5DF signal-conditioner
rocessor (CardioDynamics, Zoetermeer, The Netherlands). A
hermistor-tip balloon catheter (Criticath SP5507 TD catheter;
ecton Dickinson Infusion Therapy System, Inc, Sandy, Utah) was
nserted from the external jugular vein into the pulmonary artery to
onitor pulmonary artery and central venous pressures, positioned
o that balloon inflation produced pulmonary capillary wedge
ressure.
A left thoracotomy was performed and the pericardium opened
ongitudinally. A 20-mm Transonic flow probe (Model No.
0A165, Transonic Systems, Inc, Ithaca, NY) was placed on the
scending aorta and connected to a flow meter (Model T106,
ransonic Systems) to monitor flow and forward cardiac output
ontinuously. A fluid-filled pressure monitor catheter was inserted
nto the left atrium. An umbilical tape was snared around the
nferior vena cava (IVC).
Hemodynamic indices were recorded at steady state and after
ransient IVC occlusion to obtain LV pressure–volume loops under
arious preloads before prosthesis implantation (baseline). Venti-
atory support was transiently stopped during data acquisition
eriods. Data were digitized in real time at 200 Hz (PowerLab; AD
nstruments, Inc, Mountain View, Calif) for subsequent analysis.
picardial 2-D echocardiography equipped with harmonic imaging w
The Journal of Thoracic aas performed to evaluate LV end-diastolic (LVEDV) and end-
ystolic (LVESV) volumes for calibration of LV volumes obtained
y conductance catheter, using biplane Simpson’s rule. After base-
ine data acquisition, the conductance catheter, flow probe, and left
trial catheter were removed to prepare for cardiopulmonary by-
ass and prosthesis implantation.
ppendix E2: Extracting Hemodynamic Indices
ata analysis was performed with a custom-made Visual Basic
rogram using Excel software (Excel 2000; Microsoft Corpora-
ion, Redmond, Wash). After calibrating conductance LV volume
ata with echocardiographic data, LV ejection fraction and stroke
ork (LVSW [LVEDV – LVESV] [LV end-systolic pressure
LV end-diastolic pressure]  0.0136) were calculated and
aximum and minimum LV pressure derivatives (LVmaxdP/dt and
VmindP/dt) determined.
Load-independent indices of LV contractile function were ob-
ained from LV pressure–volume loops drawn using conductance
ata. Slope (Emax) of the end-systolic pressure–volume relation-
hip was obtained under various preloads using iterative linear
egression.35,36 Slopes of LVSW  LVEDV (preload recruitabl
troke work, PRSW) and LVmaxdP/dt  LVEDV (slope of max-
mum rate of change of pressure–end-diastolic volume relation-
hip, dE/dt) relationships were also evaluated.37 The area inside th
ressure–volume loop expresses external work. Total energy gener-
ted by the LV was approximated as the pressure-volume area, which
as circumscribed by the end-systolic pressure–volume relationship,
nd-diastolic pressure–volume relationship, and systolic trajectory of
he pressure–volume loop. LV mechanical efficiency was evaluated
y calculating the ratio of those areas (LV efficiency  external
ork/pressure  volume area).38
nd Cardiovascular Surgery ● Volume 133, Number 4 994.e1
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ETable E1. Left ventricular function at baseline and acutely
SMV
Baseline Rest
VEDV (mL) 66 17 54  13
VESV (mL) 29 8 27  8
VEF (%) 56 3 51  5
VmaxdP/dt (mm Hg · s
1 · 102) 11.8 2.4 13.9  3.9
VmindP/dt (mm Hg · s
1 · 102) 18  3.9 13.1 4.2†
VSW (mm Hg · L) 3.2 1.3 1.9  0.6†
alues are expressed as mean  SD.
VEDV, Left ventricular end-diastolic volume; LVESV, left ventricular end-sy
f change of left ventricular pressure; LVmin dP/dt, minimum rate of change
aseline. †P  .05 versus baseline. ‡P  .05 versus rest. §P  .05 SMVigure E1. Representative left ventricular pressure–volume loops
cquired at baseline and with dobutamine stimulation. LV, Leftpostimplant at rest and with dobutamine stimulation
F-SMV
Stimulation Baseline Rest Stimulation
44  10† 55 16 34 13*,§ 25  8*,‡,‡
21  4† 27  7 20 9† 13  6*,‡
52  5 50  4§ 42 4§ 47  8
20.9 4.7†,‡ 13.2  3.4 15.5  2.5 22.2  7.0†,‡
14.9 3.6 20.5 4.2 11.6 0.8* 16.2  4.0†
2.1 0.9† 2.4 0.8 1.2 0.5† 1.1  0.1†,§
stolic volume; LVEF, left ventricular ejection fraction; LVmaxdP/dt, maximum rate
of left ventricular pressure; LVSW, left ventricular stroke work. *P .001 versusentricular; DOB, dobutamine.
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